MiniMed Group, Inc. (MMED): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

MiniMed Group, Inc. (MMED) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 MiniMed Completes Separation from Medtronic NORTHRIDGE, Calif., October 15, 2026 – MiniMed (Nasdaq: MMED) today announced the completion of its separation from Medtronic plc (“Medtronic”; NYSE: MDT), marking its first day as a fully independent company. “Today marks

Event · M&A · completed
Role
target
Counterparty
Medtronic plc
Seller
Medtronic
Consideration
stock

Facts are quoted from the filing text and checked against it.

Original reporting
Published Oct 16, 2026, 12:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 16, 2026, 12:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$MMED
Neutral
high confidence
Mentioned
$MMED
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$MMEDNeutralMed
01

Why it matters

The creation of a new publicly traded entity provides a fresh investment opportunity and may trigger re‑rating by analysts.

02

Market read

The spin‑off is a primary corporate action that introduces a new ticker (MMED) to the market, likely generating short‑term trading interest.

03

What to watch

Potential regulatory approvals for MiniMed's products and integration costs of independent operations.

Relevance 6/10Novelty 8/10Timing: immediate today

Background

MiniMed announced the completion of its separation from Medtronic, exchanging Medtronic shares for MiniMed shares and ending Medtronic's equity stake.

Company-level read

Ticker impact

$MMEDNeutralHigh confidence
Context

MiniMed completed its separation from Medtronic, becoming a fully independent Nasdaq‑listed company.

Expected impact

expected pressure and volatility as the market assesses the standalone valuation; possible upside if investors view the spin‑off favorably

Evidence & confidence

First disclosure of the separation; no prior market pricing for MMED as an independent stock.

Market effects

May affect other diabetes‑care and medical‑device stocks as investors compare standalone prospects.

Primarily U.S. market impact; limited regional effect.

Low global relevance beyond the healthcare sector.

Counterpoint

If the spin‑off loses synergies with Medtronic, the standalone valuation could be pressured.

Key entities

  • MiniMed Group, Inc.

    Newly independent diabetes‑care company.

  • Medtronic plc

    Former parent, no longer holds equity in MiniMed.

Related articles

$MMEDHigh

Mizuho reiterates Outperform on MiniMed stock, cites product momentum

Mizuho reiterated an Outperform rating and $28.00 price target for MiniMed Group (MMED), citing strong product launches and regulatory approvals. The stock has gained nearly 40% over six months despite a recent 9.6% decline. MiniMed secured FDA clearance for its MiniMed Fit patch pump ahead of schedule and plans a U.S. launch in Spring 2027. Analysts predict profitability this year after a prior loss of $1.19 per share.

$MMEDHighAI 8/10

MiniMed Group FDA Clears Fit Patch Pump, Updates FY2027 Margin Guidance

MiniMed Group (MMED) received FDA clearance for its tubeless insulin pump, the MiniMed Fit, ahead of schedule. The U.S. launch is now expected in Spring 2027. The company anticipates a $162 million charge in Q3 2027, reducing EBITDA and adjusted EBITDA margins for the year to 11.3% from 16%. The underlying outlook remains unchanged according to the company.

$MMEDMedAI 8/10

MiniMed Group, Inc. announced that the U.S. Food and Drug Administration has cleared the MiniMed Fit™ patch pump, MiniMed’s first tubeless insulin pump…

MiniMed Group, Inc. (MMED) filed an SEC Form 8-K — Regulation FD Disclosure. Item 7.01 Regulation FD Disclosure. On November 16, 2026, MiniMed Group, Inc. (“MiniMed”) announced that the U.S. Food and Drug Administration (the “FDA”) has cleared the MiniMed Fit™ patch pump, MiniMed’s first tubeless insulin pump, offering people with diabetes a new different